Will a "Value-Destroying" Hospice Deal Derail Kindred?

Kindred Healthcare's attempts to buy Gentiva  seem to keep hitting the skids. First there were the multiple board rejections. And now rumors abound that Gentiva is looking to buy out fellow hospice and home health company Amedisys . How credible are the rumors?

Credible enough that Kindred sent Gentiva a note decrying the potential of this "value-destroying and highly levered transaction." And Kindred's management made clear that they may pull their offer if the Amedisys buyout occurs.

So, should Gentiva buy Amedisys? Should Kindred buy Gentiva?

Motley Fool health care analysts Michael Douglass and David Williamson answer in the video below.

Creating value instead
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

The article Will a "Value-Destroying" Hospice Deal Derail Kindred? originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story